SynthesisBMC pulmonary medicine2020
The association between cystatin C and COPD: a meta-analysis and systematic review.
Synthesis in BMC pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Association Between Serum Cystatin C and Thyroid Diseases: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Relationship between serum cystatin C and long-term mortality in patients with self-reported COPD: evidence from two large population-based surveys.BMJ open respiratory research · 2026Article
- Construction of nomogram for predicting pulmonary hypertension on echocardiography in chronic obstructive pulmonary disease: a single-center retrospective study.Open medicine (Warsaw, Poland) · 2026Article
- Association between handgrip strength to Cystatin C ratio and hearing loss: insights from the CHARLS study.Journal of health, population, and nutrition · 2025Article
- Association between serum cystatin C and chronic lung disease in middle-aged and elderly Chinese: a CHARLS cross-sectional study.Scientific reports · 2025Article
- Proteomic Risk Score of Increased Respiratory Susceptibility: A Multicohort Study.American journal of respiratory and critical care medicine · 2025Article
- Low Skeletal Muscle Mass and Clinical Outcomes in Chronic Obstructive Pulmonary Disease.Tuberculosis and respiratory diseases · 2023Article
- Correlation of TNF-α, Cys C, and NLRP3 inflammasomes with venous ulcers in patients with lower extremity varicose veins.American journal of translational research · 2023Article
- Performance and Determinants of Serum Creatinine and Cystatin C-Based GFR Estimating Equations in South Asians.Kidney international reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, many studies have discovered that cystatin C (Cys C) may play an important role in respiratory diseases, especially in chronic obstructive pulmonary disease (COPD). However, the findings of these studies were inconsistent. This systematic review and meta-analysis aimed to assess the relationship between serum Cys C and COPD.
methodsWe conducted a systematic literature search in PubMed, Embase, Web of Science, Wanfang databases, and the China National Knowledge Infrastructure. The standardized mean difference (SMD), Fisher's Z-value and 95% confidence interval (CI) were calculated to investigate the effect sizes. Subgroup analyses were performed on disease status, ethnicity, assay method, and study design. Sensitivity was performed, and publication bias was assessed.
resultsA total of 15 studies, including 4079 COPD patients and 5949 controls, were included in this meta-analysis. The results showed that serum Cys C levels in patients with COPD were significantly higher than those in controls (SMD = 0.99, 95% CI =0.62-1.37, P < 0.001), especially in AECOPD (SMD = 1.59, 95% CI =1.05-2.13, P < 0.001), and there were statistically different among AECOPD and SCOPD (SMD = 0.35, 95% CI =0.10-0.59, P = 0.005). The serum Cys C levels were negatively correlated with FEV1%pre (Z = - 0.45, 95%CI = -0.58--0.32, P = 0.011) and FEV1/FVC (Z = - 0.32, 95%CI = -0.50--0.14, P = 0.006). The serum Cys C levels were independent of ethnicity, assay method, and study design.
conclusionSerum Cys C levels were associated with COPD and COPD exacerbation, and they were inversely correlated with FEV1%pre and FEV1/FVC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.